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Dual conformations for the HIV-1 gp120 V3 loop in complexes
with different neutralizing Fabs
RL Stanfield1, E Cabezas1†, AC Satterthwait1†, EA Stura1‡, AT Profy2§
and IA Wilson1,3*
Background: The third hypervariable (V3) loop of HIV-1 gp120 has been
termed the principal neutralizing determinant (PND) of the virus and is involved
in many aspects of virus infectivity. The V3 loop is required for viral entry into
the cell via membrane fusion and is believed to interact with cell surface
chemokine receptors on T cells and macrophages. Sequence changes in V3
can affect chemokine receptor usage, and can, therefore, modulate which types
of cells are infected. Antibodies raised against peptides with V3 sequences can
neutralize laboratory-adapted strains of the virus and inhibit syncytia formation.
Fab fragments of these neutralizing antibodies in complex with V3 loop
peptides have been studied by X-ray crystallography to determine the
conformation of the V3 loop.
Results: We have determined three crystal structures of Fab 58.2, a broadly
neutralizing antibody, in complex with one linear and two cyclic peptides the
amino acid sequence of which comes from the MN isolate of the gp120 V3
loop. Although the peptide conformations are very similar for the linear and
cyclic forms, they differ from that seen for the identical peptide bound to a
different broadly neutralizing antibody, Fab 59.1, and for a similar peptide
bound to the MN-specific Fab 50.1. The conformational difference in the
peptide is localized around residues Gly-Pro-Gly-Arg, which are highly
conserved in different HIV-1 isolates and are predicted to adopt a type II β turn.
Conclusions: The V3 loop can adopt at least two different conformations for
the highly conserved Gly-Pro-Gly-Arg sequence at the tip of the loop. Thus, the
HIV-1 V3 loop has some inherent conformational flexibility that may relate to its
biological function.
Introduction
Human immunodeficiency virus 1 (HIV-1) is a member of
the lentivirus subfamily of retroviruses. The exterior of
the membrane-enveloped virus is embedded with multi-
ple copies of the proteins gp120 and gp41, which are syn-
thesized as a single protein precursor (gp160) and then
cleaved, but remain in a noncovalent association on the
membrane surface [1]. These viral antigens have been
implicated in viral cell entry; gp120 binds to CD4 and
then to at least one other coreceptor on the cell surface,
before gp41-mediated fusion of the viral and target cell
membranes. Recently, several β-chemokine receptors have
been implicated as the viral secondary receptors, with
CXCR4 serving as the primary coreceptor for T-cell tropic
(T-tropic) or T-cell line adapted (TCLA) syncytia-induc-
ing (SI) isolates and CCR5 serving as the major coreceptor
for macrophage-tropic (M-tropic) nonsyncytia-inducing
(NSI) isolates (for reviews, see [2,3]). Viruses that require
CXCR4 for their coreceptors are termed ‘X4’ viruses,
whereas viruses that require CCR5 are termed ‘R5’ viruses.
Dual tropic viral strains have been identified that can use
both coreceptors and, thus, are termed R5X4 viruses; some
alternative coreceptors have also been identified that can
be used by the virus to enter cells. 
The third hypervariable (V3) domain of gp120 is a disul-
fide-linked loop of approximately 40 amino acids with a
high degree of sequence diversity among different viral iso-
lates [4–6]. The V3 loop is one of the major immunogenic
sites on the virus and is sometimes called the principal neu-
tralizing determinant (PND) [7]. The accessibility or expo-
sure of the V3 loop on gp120 appears to vary depending on
viral isolate type and increases significantly when the virus
interacts with CD4 through a conformational change that is
triggered in gp120 [8,9]. The V3 loop then becomes more
sensitive to neutralizing antibodies and proteases as a result
of the gp120–CD4 interaction. Sequence changes in V3
can alter viral cell tropism [10,11], antibody neutralization
[12–14], neutralization of soluble CD4 [15], syncytium for-
mation [11,16] and chemokine receptor usage [17]. It has
Addresses: 1The Scripps Research Institute,
Department of Molecular Biology, 10550 North
Torrey Pines Road, La Jolla, CA 92037, USA,
2Repligen Corporation, 117 Fourth Avenue,
Needham, MA 02194, USA and 3The Scripps
Research Institute, Skaggs Institute for Chemical
Biology, 10550 North Torrey Pines Road, La Jolla,
CA 92037, USA.
Present addresses: †The Burnham Institute, 10901
North Torrey Pines Road, La Jolla, CA 92037, USA,
‡Department d’Ingenierie et d’Etude des Proteines,
BAT 152 CEA/SACLAY, 91191 Gif sur Yvette
Cedex, France and §Procept, Inc., 840 Memorial
Drive, Cambridge, MA 02139, USA.
*Corresponding author.
E-mail: wilson@scripps.edu
Key words: antibody–peptide complex, Fab
fragment, HIV-1, vaccine, X-ray crystallography
Received: 8 October 1998
Revisions requested: 11 November 1998
Revisions received: 23 November 1998
Accepted: 1 December 1998
Published: 29 January 1999
Structure  February 1999, 7:131–142
http://biomednet.com/elecref/0969212600700131
© Elsevier Science Ltd ISSN 0969-2126
Research Article 131
been noted that T-tropic V3 sequences are usually more
basic in charge than M-tropic sequences through accumula-
tion of positively charged residues in regions on either side
of the GPGR tip of the loop [18,19]. As no easily discern-
able pattern relates specific changes in V3 residues to phe-
notypic changes, it is likely that conformational variations in
gp120 and the V3 loop that arise from particular V3 loop
sequences could modulate gp120 function. Although the
crystal structure of a ternary complex between gp120, CD4
and an antibody Fab fragment has at last been determined
[20–22], the gp120 was modified by removing several loops
including V3. Thus, the paucity of structural information on
the V3 loop still needs to be addressed. 
In early work by La Rosa et al. [4–6], an analysis of 245 dif-
ferent HIV-1 V3 loop sequences showed that some amino
acid positions in the loop are highly variable in amino acid
composition, whereas others, especially those near the tip of
the loop, are highly conserved; for example, examination of
the MN sequence IHIGPGRAFY reveals that these amino
acids are found at their respective positions in 94, 47, 82, 98,
95, 98, 91, 83, 72 and 80% of the other 244 isolates. The
GPGR sequence is highly conserved in all known sequences
of subtype B, whereas other group M isolates are character-
ized by the highly related GPGQ sequence at this position.
The high degree of conservation of some of these amino
acid positions suggests that they have a key structural and
functional role and are important in some aspect of virus
infectivity, such as modulation of the conformation of the
V3 loop, or for modulating the interaction with coreceptor.
The LaRosa et al. study [4–6] also predicted the secondary
structure for their V3 consensus sequence (CTRPNNNT-
RKSIHIGPGRAFYTTGEIIGDIRQAHC) to consist of an
extended β strand, a type II β turn around residues GPGR,
a β strand and then an α helix. This secondary structural
prediction was carried out for all 245 sequences, with 93%
predicted to have the extended β strand around residues
SIHI and 66% predicted to have the short helix at residues
DIRQ. Pro, Gly and Arg are the most commonly found
residues in positions i+1, i+2 and i+3 of a type II β turn,
whereas Gln is the second most commonly found residue at
position i+3 [23].
We have been investigating several HIV-1 neutralizing
antibodies and their complexes with V3 peptides in order to
determine the tertiary conformation of the V3 loop and to
understand why some antibodies are viral-specific while
others recognize many different viral strains. These neutral-
izing antibodies recognize the V3 epitope as a free peptide
in the soluble gp120 protein and on the intact HIV-1 virus.
Knowledge of the conformation of this loop may help to
explain coreceptor usage and the changes that take place in
the virus upon conversion from a primary M-tropic isolate to
the T-tropic strains associated with disease progression. A
panel of antibodies, which were raised against the same 40
amino acid V3 peptide RP70 [24] (Figure 1), neutralize the
virus by preventing viral–cell membrane fusion. It has long
been thought that these and other V3-specific antibodies
do not interfere with CD4 binding. Recent studies using
intact viral particles rather than soluble monomeric gp120,
however, indicate that V3 neutralizing antibodies may also
prevent the binding of HIV-1 to CD4+ human cells [25].
Previously, we have reported the structures of two anti-
body Fab fragments, 50.1 and 59.1, in complex with V3
peptides [26–29]. Fab 50.1 is reported to be highly spe-
cific for the MN viral strain (T-tropic, SI), whereas 59.1 is
reported to strongly neutralize IIIB (T-tropic, SI) and
weakly neutralize MN [24]. The X-ray structures for V3
peptides in complex with Fabs 50.1 and 59.1 agreed well
with the La Rosa et al. [4–6] predictions up to the con-
served GPGR tip of the loop. In the 50.1–peptide complex,
eight amino acid residues were ordered in the antibody
combining site (CKRIHIGPG). Residues CKRIHI were
in an extended β conformation with the two Ile residues
buried in tightly fitting hydrophobic pockets in the anti-
body combining site and the GPG forming the start of
a turn. The first Gly residue had torsion angles in the
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Figure 1
Sequences of the V3 loop peptides used in crystallization of the
peptide–Fab complexes. Fabs 58.2, 50.1 and 59.1 were all raised
against the 40 amino acid, disulfide-linked peptide RP70, which has
the MN viral sequence. A disulfide bond links the two cysteine
residues as shown. Aib142 is the linear peptide crystallized with both
58.2 and 59.1. The Aib residue in peptide Aib142 is an α-
aminoisobutyric acid [NHC(CH3)2C(O)] and replaces an Ala residue in
the original sequence. The His loop and Ser loop cyclic peptides are
constrained with a hydrazone linkage between residues J and Z, as
shown in detail at the bottom of the figure. In the crystal structure of
these cyclic peptides, the first residue (J) is referred to as ArnP1, and
consists of atoms N-CH-CH2-CH2-CH2-C-O. The second residue is
then His/SerP315, the third residue is IleP316, and so on. The last
naturally occurring residue is PheP324 which is then followed by GlyP10,
GlyP11(Z) and GlyP12. The N atoms of ArnP1 and GlyP11 are connected
by the hydrazone linkage.
RP70 INCTRPNYNKRKRIHIGPGRAFYTTKNIIGTIRQAHCNIS
Serine loop JSIGPGRAFGZG- NH
Histidine loop JHIGPGRAFGZG- NH
Aib142 YNKRKRIHIGPGRAibFYTTKNIIGC
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epsilon (ε) region of Ramachandran space, a region usually
only available to Gly residues, centered around φ = 90°
and ψ = 180°.  The PG had torsion angles appropriate for
a type II β turn. In the 59.1–peptide complex, 10 amino
acid residues were visible (HIGPGRAFYT). Five of these
residues had structural counterparts in the peptide from
the 50.1 complex (HIGPG), and displayed very similar
mainchain torsion angles. Following the type II β turn
around GPGR, we observed a double bend consisting of
a type I turn for residues GRAF (in [28], this turn is
referred to as type III; the type III turn is a variant of the
type I turn and is usually classified as type I) and a
type I turn around RAFY. The sidechain of the Arg residue
is bound in a deep, negatively charged pocket on the anti-
body surface.
The individual peptide structures from the 50.1 and 59.1
complexes could be pieced or spliced together to make a
more complete model for a 13-residue section of the V3
loop [29] that included the GPGR tip. Contrary to the
previous predictions [4–6] of a single tight turn around
GPGR, a much broader double turn was found that con-
sisted of a type II turn around GPGR and a double bend
(type I, GRAF; type I, RAFY) around GRAFY. The Ala
residue in the double bend had α-helical torsion angles of
φ = –60°, ψ = –45°, similar to one of the two preferred con-
formations for the conformationally restricted residue
Aib [α-aminoisobutyryl residue –NHC(CH3)2C(O)], which
normally adopts torsion angles of –57°,–47° or +57°,+47°
[30,31]. We surmised that replacement of the Ala residue
with an Aib residue could constrain the peptide and
provide a more rigid scaffold for vaccine or drug design
around this template. Nuclear magnetic resonance (NMR)
studies of such an Aib-containing peptide confirmed that
additional structure was indeed conferred on the peptide
in aqueous solution [29]; the X-ray structure determina-
tion of Fab 59.1 with the Aib-containing peptide showed
that the Aib residue made no significant changes to the
peptide conformation, as expected [29]. The Aib residue
was not necessary for binding or for crystallization, as Fab
59.1 could be crystallized isomorphously with peptides
that were identical except for the Ala→Aib mutation.
Another attempt to restrict conformation of the V3 pep-
tides involved using a synthetic hydrogen bond mimic incor-
porating a hydrazone bond. These hydrogen bond mimics
are designed to replace a CO–HN hydrogen bond within a
β-hairpin structure, thus cyclizing the peptide into a con-
strained hairpin structure.
Here, we describe the crystal structure of Fab 58.2, a
highly potent and broadly neutralizing antibody that has
been reported to neutralize both T-tropic and M-tropic
viral strains, as well as several strains that have been pas-
saged only once or twice [24]. We report the structures for
Fab 58.2 in complex with one linear Aib-containing peptide
and two cyclic, constrained peptides.
Results and discussion
Structure determination and refinement
The crystal structures for Fab 58.2 in complex with one
linear (Aib142; Figure 1) and two hydrazone-linked cyclic
peptides (His loop, Ser loop; Figure 1) have been deter-
mined to 2.0 Å (Aib142) and 2.8 Å (His loop and Ser loop).
Data collection and refinement statistics are summarized in
Table 1. All structures were determined by the molecular
replacement (MR) method using previously determined
Fab structures (see Materials and methods section). The
crystals of the two Fab–cyclic peptide complexes were iso-
morphous, as a result of only a single amino acid difference
in their peptides (His315→Ser). All structures were refined
with the X-PLOR simulated annealing refinement proto-
col [32], using the Engh and Huber parameter set [33] and
a bulk-solvent correction. The Fab molecules are num-
bered according to standard convention [34] with light and
heavy chain identifiers L and H, respectively. The pep-
tides are numbered according to the BH10 isolate
sequence [35] with a P chain identifier (RP313 IP314 HP315
IP316 GP319 PP320 GP321 RP322 AP323 FP324 YP325). Note that the
sequential numbering system is interrupted due to a two
amino acid insert, after P316, that occurs in the IIIB isolate.
The Fab 58.2–Aib142 coordinates contain Fab residues
L1–L212, H1–H230 and peptide residues P313–P325
(11 residues). The Fab 58.2–His-loop coordinates contain
Fab residues L1–L212, H1–H230 and the cyclic peptide
with the complete hydrazone linker (P1–P12; see Figure 1).
The Fab 58.2–Ser-loop coordinates contain Fab residues
L1–L211, H1–H230 and the cyclic peptide minus the
hydrazone linker (P2–P12).
The Fab–Aib142 peptide complex structure (Figure 2a)
was determined to 2.0 Å resolution. Analysis of the
Ramachandran plot by PROCHECK [36] shows that 89%
of the residues are in most favored positions with three
residues in disallowed regions. These ‘disallowed’ residues
include two residues in a disordered loop in the constant
heavy chain (residues H128–H136), which almost always
displays high displacement parameters in other antibody
structure determinations [37] and residue AlaL51 (φ = 69°,
ψ = –53°), which is the i+2 residue in a distorted type I′
turn in most Fab L2 complementary determining region
(CDR) loops [38]. 
Two Fab–cyclic peptide structures (Figure 2b,c) were
determined, both to 2.8 Å resolution. These structures
differ at only one residue in the peptide (Figure 1). The
Rfree was not monitored during the Ser loop refinement as
this particular structure was determined prior to the intro-
duction of the Rfree validator. Only one bound water was
included in each model due to the moderate resolution.
Ramachandran plot analysis of the His loop complex by
PROCHECK [36] shows that 81% of the residues are in
most favored positions, with three residues in disallowed
regions (two residues from the H128–H136 loop and AlaL51).
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The Ser loop complex has 87% of the residues in most
favored regions with five residues in disallowed regions
(two in the H128–H136 loop, the C-terminal residue of the
heavy chain, AlaL51 and LysH64, which is the i+1 residue of
a type II′ turn). 
Structure description and comparisons
Fab 58.2 is a mouse IgG1 κ antibody. The elbow angles for
Fab 58.2 are 174.3°, 144.8° and 144.3° in the Aib142, His
loop and Ser loop complexes, respectively. The 58.2 CDR
loops L1, L2, L3 and H2 belong to canonical classes 5, 1, 1
and 1, as classified previously [39,40]. The 58.2 H1 CDR
loop has a one amino acid insert following residue 35 and so
should belong to canonical class 2. Other Fabs with H1
loops of this length are AN02 (PDB accession code 1baf;
[41]) and N10 (1nsn; [42]); however, the H1 loops in both
58.2 and N10 differ from the expected canonical structure
around several residues at their tips and also differ in this
region from each other (Figure 3). Not surprisingly, a ten-
dency for an increase in flexibility is seen as the H1 loop
increases in length. Fab 58.2 has a long CDR H3 with a
nine amino acid insert after residue 100. Previously deter-
mined structures with H3 loops of this length include KOL,
3D6 and R45-45-11 (accession codes 2fb4 [43], 1dfb [44]
and 1ikf [45], respectively). The conformation of the base
of the H3 loop is dictated by residues AlaH93, ArgH94 and
AspH101. This combination of residues results in a ‘kinked’
base structure, as expected [39,46], with the sidechain of
AspH101 forming a salt bridge with ArgH94 and the mainchain
carbonyl oxygen of H100I (the residue preceding H101)
forming a hydrogen bond to TrpH103 Nε1.
The linear Aib142 peptide is 24 amino acids with an Aib
residue replacing AlaP323 (Figure 1). Electron density is
clearly visible for 11 of the 24 residues, RIHIGPGRAibFY
(Figure 4a,b). The peptide has an extended conformation
for residues RIHI, which connect to a type I (αR→αR)
turn around residues GPGR. A type VIa (βP →αR) turn is
found for residues GRAibF and a type I turn is found
around residues RAibFY, making residues GRAibFY a
double bend. Residue ArgP322 is bound in a deep pocket
in a highly negatively charged antibody combining site
(Figure 5a), forming charge–charge interactions with
residues AspL94 and GluH95 (Figure 5b). The bound por-
tions of the cyclic peptides have a very similar conforma-
tion to the bound portions of the linear peptide. Clear
electron density is present for most of the cyclic peptides,
with a small break in density around the hydrazone linker
in the His loop complex, and weak density for the linker
in the Ser loop complex (Figure 4c,d). The hydrazone
linker has been left out of the Ser loop model because of
its weak electron density.
The three peptides bind to the antibody in virtually
identical orientations, with the peptide lying flat on the
Fab surface and residue ArgP322 protruding into a deep,
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Table 1
X-ray diffraction data and refinement statistics for Fab 58.2 complexes.
Peptide Aib142 His loop Ser loop
Space group C2 P21212 P21212
Unit cell (Å) 72.9, 71.9, 88.2 96.1, 114.7, 49.5 95.5, 115.5, 49.6
β = 98.3°
Number of crystals 3 1 1
Resolution (Å) 43.6–2.0 24.0–2.8 47.8–2.8
Last shell (Å) 2.05–2.0 3.02–2.8 2.98–2.8
Observations 183,103 (9505) 44,763 (4678) 47,266 (9337)
Unique reflections 30,460 (2014) 12,923 (2287) 13,951 (2259)
Rmerge (%)/ Rsym (%) 10.6 (54.7) 7.6 (28.8) 7.2 (21.8)
Completeness (%) 99.6 (98.5) 91.9 (82.8) 98.9 (97.7)
<I/σI> 29.5 (3.4) 7.5 (1.0) 13.2 (1.5)
Generator Siemens M18X; Rigaku RU-300 Rigaku RU-200 Siemens M18X
Optics Supper long mirrors; monochromator Monochromator Supper double mirrors
Detector Mar 30 cm; R-axis II Xuong-Hamlin multiwire Siemens X1000
Data reduction program HKL [81] Xuong-Hamlin [82] XENGEN [83]
Rcryst (%)* 19.6 (31.8) 18.5 (27.6) 20.0 (37.7)
Rfree (%)† 25.6 (38.2) 30.5 (36.6) –
Rmsd bond lengths (Å) 0.010 0.012 0.008
Rmsd bond angles (°) 1.82 1.87 1.59
Number of water molecules 120 1 1
Values given in parentheses are for the highest resolution shell.
*Rcryst = Σh Fobs(h)–Fc(h)/ΣhFobs(h), where Fobs and Fc are
the observed and calculated structure-factor amplitudes for reflection
h = (h,k,l). †Rfree is calculated with 10% (5% for the His loop–Fab
complex) of the data never used in the refinement. Rfree was not
calculated for the Ser loop complex. The Rcryst and Rfree are calculated
using all data with F/σF>0. A bulk-solvent correction as implemented in
X-PLOR [72] was applied to all data sets.
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Figure 2
Stereoviews of the X-ray structures of the Fab
58.2–peptide complexes. (a) The Fab
58.2–Aib142 complex. The Cα trace is
shown for the light chain (cyan) and heavy
chain (blue) of the Fab. All atoms of the bound
peptide are shown in red. Every tenth Cα
atom is highlighted with a sphere and some
atoms are labeled. (b) The Fab 58.2–His loop
complex. (c) The Fab 58.2–Ser loop complex.
Figures were made with the program
MOLSCRIPT [74].
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negatively charged pocket on the Fab surface (Figure 5a).
The surface area [47] buried by the peptide on the Fab is
666, 609 and 597 Å2 for the Aib142, His loop and Ser loop
peptides, respectively. The corresponding buried surface
area on the peptides is 578, 540 and 487 Å2 . The Fab uses
five of its six CDR loops to bind peptide; CDR L2 is not
used and CDR H1 makes only minor contacts. This
pattern of CDR usage is typical for antihapten and anti-
peptide antibodies [48]. A total of 124, 103 and 77 van der
Waals contacts are made between the Fab and peptide for
the Aib142, His loop and Ser loop complexes, respectively
(Table 2). In each complex, charge–charge interactions are
found between ArgP322 of the peptide and AspL94 and
GluH95 of the Fab (Table 3). In the Aib142 peptide, an
additional charge–charge interaction is made between
ArgP313 and AspL28. A total of 11, 7 and 7 hydrogen bonds
and salt bridge interactions are made between the pep-
tides and Fab in the Aib142, His loop and Ser loop com-
plexes, respectively (Table 3). The size and features of
this interaction surface are similar to those of other Fab–
peptide complex structures [49]. The Fab conformations
are very similar between the different complexes as shown
by the small differences in VL–VH pairings (less than 1.4°)
between the complexes and the root mean square devi-
ations (rmsds) for the individual domains, which range
from 0.31 Å to 1.20 Å. One loop in the constant heavy
chain (H128–H136), which frequently shows high thermal
displacement parameters in Fab crystal structures [37],
accounts for the high rmsds (0.83–1.20 Å) for the CH1
regions. Removal of this loop from rmsd calculations
results in rmsds of 0.61–0.72 Å.
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Figure 3
Comparison of the conformation of the H1 loops of Fabs 58.2 (red),
N10 (yellow) and AN02 (blue). The coordinates of Fabs N10 and
AN02 were obtained from the Protein Data Bank (accession codes
1nsn and 1baf, respectively).
Figure 4
Electron density for the V3 peptides bound to
Fab 58.2. (a) In the electron density for the
58.2–Aib142 complex, 11 residues of the 24-
mer peptide Aib142 are visible. The simulated
annealing (SA) omit electron-density map for
peptide Aib142 is shown for the region
around residues GPGR, which form a type I
β turn. (b) SA omit electron density for
peptide Aib142 showing the region around
residues RAibFY. (c) SA omit electron density
for the His loop peptide. (d) SA omit electron
density for the Ser loop peptide. The
hydrazone linker was not included in this
model due to weak electron density; the
approximate position of the linker is indicated
by a dotted line. All maps are contoured at a
1σ level. Figures were made with
BOBSCRIPT [75] and Raster3D [76,77].
Although the resolution of the His loop and Ser loop struc-
tures is insufficient to allow accurate placement of ordered
water molecules, one strong peak of density in the Fab
binding site of all three structures was assigned as a water
position. Additionally, 120 water molecules were included
in the 2.0 Å resolution refinement of the Aib142 complex.
Six of these water molecules are found buried at the
Fab–peptide interface (W12, W41, W62, W67, W72, W84). 
The conclusions from epitope mapping experiments of
antibody 58.2 agree well with the structural results. The
epitope specificity for 58.2 was determined previously by
screening a peptide display library expressing 1.5 × 108
unique 20 amino acid peptide sequences against 58.2 [50],
as well as by epitope mapping, where 266 unique 14-mer
peptides were prepared, with each amino acid position
replaced with all amino acids (except Cys) (peptide KRKR-
IHIGPGRAFY) [50]. Residues KRKRI (P310–P314) could
be replaced by most of the other amino acids, indicating
that they are not important for peptide binding to Fab 58.2.
HisP315 could be replaced with any amino acid except Gly,
Pro and Thr. IleP316 could only be replaced with Glu, Leu,
Met and Val. GlyP319 could not be replaced by any other
amino acid. ProP320 could only be replaced by Ile. The
second GlyP321 was not so important, as it could be replaced
with all amino acids except Ile, Pro, Ser, Thr, Val and Trp.
ArgP322 could not be substituted, whereas AlaP323 could be
replaced with any amino acid except Pro. The PheP324
could be replaced with Asp, Ile, Lys, Gln, Arg, Ser, Thr, Val
and Trp. These epitope mapping results indicate that
residues GlyP319, ProP320 and ArgP322 are especially impor-
tant for antibody binding, in agreement with the crystal
structure that shows that ArgP322 forms a charge–charge
interaction with the Fab and residues GlyP319 and ProP320
are critical for determining the conformation of the tip of
the V3 loop. Residue GlyP319, which of course is a highly
conformationally flexible residue, may also be important for
allowing the loop to adjust to more than one distinct confor-
mation. GlyP321, the i+2 residue in the type I β turn of the
peptide in the 58.2–peptide complexes, is not absolutely
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Figure 5
The Fab 58.2 binding pocket with the Aib142
peptide bound. (a) GRASP [78]
representation of the antibody combining site
with Aib142 peptide bound. Negatively
charged regions are colored in red and
positively charged regions are colored in blue.
(b) Stereoview of the combining site. The
contacting residues of the light and heavy
chains are shown in cyan and blue,
respectively; the peptide is in yellow.
required, in agreement with the diversity of residues that
are found at the i+2 position of type I turns [23]. This
result contrasts with the alanine replacement experiment
on peptide binding to Fab 59.1 [24,28]. When GlyP321 is
replaced by an Ala residue, the affinity of Fab 59.1 for the
peptide is reduced to about 32% of that of the native
peptide, in good agreement for the strong preference for a
Gly residue at the i+2 position of a type II turn [23], as
found in the 59.1–peptide complex. 
Two different V3 conformations
The most notable feature of the V3 peptide conformation
while bound to Fab 58.2 is that it differs from the two
previously determined structures for the same or similar
peptide in complex with two other Fabs. The previously
determined V3 loop structures were for peptide complexes
with Fab 50.1, where the peptide epitope was identified
as CKRIHIGPG, and with Fab 59.1, where the peptide
epitope was HIGPGRAFYT. The three antibodies were
all generated against the same peptide immunogen, RP70
[24] (Figure 1). The five residues (HIGPG) that are struc-
turally ordered in peptides bound to both Fabs 50.1 and
59.1 could be superimposed with low rmsds (Figure 6)
[28,29]. These two peptides both adopt torsion angles for
a type II β turn around residues GPGR. Thus, it was sur-
prising to observe that the peptide bound to Fab 58.2
had torsion angles for a type I β turn around these same
residues. The mainchain torsion angles for these four
residues (GPGR) differ significantly between the two
peptide-conformational types. The residues before and
after the GPGR sequence, however, share very similar
mainchain torsion angles (Table 4). The second β turn,
around residues GRAibF (or GRAF), is type I in the 59.1
complex (type I [αR→αR] turns have average torsion angles
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Table 2
Van der Waals contacts between Fab 58.2 and bound peptides.
Peptide residue In all complexes Aib142 His loop Ser loop
ArgP313 AspL28 AlaH100D TyrH100E
IleP314/ArnP1 TyrH100E TyrH100G
HisP315/SerP315 TyrH100E AspL28 AlaL30 PheL32 AspL28 AlaL30 PheL32 TyrH100
TyrH100 AlaH100D TyrH100F TyrH100G
IleP316 PheL32 TyrH33 TyrH100G PheL27D TyrH100G
GlyP319 PheL32 HisL92 SerL91 SerL91
ProP320 PheL27D HisL92
GlyP321 HisL92 GluL93 AspL94
ArgP322 SerL91 GluL93 AspL94 LeuL96 GluH95 HisH35a TyrH50 TyrH50
AlaP323/AibP323 AspL94 TyrH50 AsnH58 AsnH58
PheP324 TyrH50 HisH52 GlyH56 ThrH57 TyrH33 SerH54 TyrH33
TyrP325/GlyP10 PheL27D TyrH33 HisH52 TyrH33 HisH52
GlyP11 TyrH53
Van der Waals contacts were calculated with the program CONTACSYM [84] using standard van der Waals radii [85]. The Fab residues
contacted in all complexes are shown first, followed by additional contacts that are specific to the individual complexes.
Table 3
Hydrogen bonds and salt bridge interactions (Å) in Fab 58.2–peptide complexes.
Peptide atom Fab atom Aib142 His loop Ser loop
P313 Arg NH2 L28 Asp OD2 2.8
P313 Arg NH1 L28 Asp O 3.2
P313 Arg O H100e Tyr N 2.9
P315 His/Ser N H100e Tyr O 2.7
P315 His/Ser ND1 H100e Tyr O 3.3
P319 Gly N L92 His O 3.0 2.9 3.1
P321 Gly O L94 Asp N 3.3 3.3 3.3
P322 Arg NE L94 Asp OD1 2.8 2.9
P322 Arg NH2 H95 Glu OE1 3.0 2.8 2.8
P322 Arg NH1 H95 Glu OE2 2.9 2.8 3.0
P323 Aib/Ala N L94 Asp OD2 2.9 3.1 2.9
P324 Phe O H33 Tyr OH 2.8 2.7
P10 Gly O H52 His NE2 3.0
Hydrogen bonds were calculated with HBPLUS [86].
of φ = –60°, ψ = –30° and φ = –90°, ψ = 0° for the i+1 and
i+2 residues), and type VIa in the 58.2 complex (type VIa
[βP→αR] turns have average torsion angles of φ = –60°,
ψ = 120° and φ = –90°,ψ = 0° for the i+1 and i+2 residues)
with the torsional angles of residues AFY being highly
similar in all peptide complexes (Table 4). So, the pep-
tides bound to Fabs 59.1 and 58.2 both contain a β turn
followed by a double bend, but the different torsion angles
for the central GPGR residues change the precise charac-
ter of these turns and bends. NMR studies of the Aib142
peptide in solution have provided evidence for popula-
tions of both type I and II turns around residues GPGR
[29], which is in good agreement with the two peptide
conformations that we observe in the crystal structures of
the V3 loop with different Fabs.
Several other NMR studies of V3 peptide conformation
have been carried out in solution for both linear and cyclic
peptides of varying length and sequence. These studies
have shown that the V3 loop by itself is largely disordered
in water, but contains a population of tight turns for residues
GPGR. The NMR studies show evidence for type II turns
[51,52], both I and II turns [53–56], nonspecific β turns
[57] and a double turn, similar to that seen in the 59.1-
peptide X-ray structure [58]. NMR studies have also sup-
ported the proposal that glycosylation of the V3 peptide
can affect its conformation [59,60] and that sequence
changes affect the conformation [61]. NMR studies of an
antibody–V3 loop peptide complex have also been carried
out [62,63] but indicated only that the peptide forms a
loop with residues GPGR at the tip, with no more detailed
information being reported. Interestingly, a search of the
Brookhaven Protein Data Bank [64] for proteins contain-
ing the sequence GPGR identified two different proteins,
but neither were in a type I or II β turn. In scorpion toxin
II (PDB codes 1ptx and 1aho  [65]), these residues form a
wide, undefined turn near the C terminus of the protein
(i+1, φ = –65°, ψ = 150°; i+2, φ = 115°, ψ = 135°; βP→ε),
whereas in chaperonin-10 (PDB code 1lep [66]) the GPGR
residues are part of a β strand. Additionally, in a recently
reported X-ray structure [67] of the major histocompatibil-
ity complex (MHC) class I H-2Dd–HIV-1 peptide (RGP-
GRAFVTI) complex, the GPGR is in an extended con-
formation, as expected for peptides complexed with MHC
class I molecules.
Correlation of structure with function
We clearly observe two different conformations for the V3
loop while bound to different neutralizing antibodies, and
two conformations for the tip of the loop in solution [29].
These V3 loop conformations are biologically relevant, as
the antibodies bind to viral gp120 to effect their neutral-
ization activity. These conformations may represent two
different and distinct secondary structural motifs that
may or may not relate to viral phenotype, or they could
merely indicate that the V3 loop is flexible and able to
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Figure 6
Dual conformations of the V3 loop. The peptides bound to Fabs 50.1,
59.1 and 58.2 are superimposed using the Cα atoms of residues with
similar torsion angles (Table 4). The 50.1 peptide is in yellow, the 59.1
peptide is in purple, and the Aib142 and His loop peptides bound to
58.2 are colored in blue and green, respectively. The hydrazone
linkage in the His loop peptide is indicated by a straight connection. All
four peptides share similar mainchain torsion angles for residues IHI
and AF, the residues on either side of GPGR. The GPGR region in the
58.2 peptide (type I turn) differs from that seen in the 50.1 and 59.1
peptides (type II turn). Figure made with the program MIDAS [79,80]. 
Table 4
Mainchain dihedral angles (°) for V3 peptides bound to Fabs
50.1, 59.1 and 58.2.
50.1 Peptide 59.1 Peptide 58.2 Aib142
peptide
φ ψ φ ψ φ ψ
CysP311
LysP312 –119 –169
ArgP313 –144 135 163
IleP314 –67 124 –122 144
HisP315 –89 134 144 –107 110
IleP316 –124 141 –133 –169 –124 137
GlyP319 102 173 79 –172 –58 141
ProP320 –63 170 –73 165 –63 –24
GlyP321 86 60 9 –95 –1
ArgP322 –64 –41 –65 141
Ala/AibP323 –60 –46 –50 –42
PheP324 –94 19 –107 40
TyrP325 –49 –22 –68 161
ThrP326 –126
adopt different conformations. The only reported crystals
of gp120 to date have been obtained for protein where this
loop was truncated at its base [20–22]; crystals of gp120
with the intact loop have not yet been reported.
Biological implications
Human immunodeficiency virus 1 (HIV-1) is a mem-
brane-enveloped virus, the exterior of which is embed-
ded with multiple copies of the proteins gp120 and gp41.
The third hypervariable loop (V3) of gp120 is involved
in many aspects of virus infectivity and has, therefore,
been the subject of much interest. The high degree of
conservation of the Gly-Pro-Gly-Arg/Gln motif at the tip
of the gp120 V3 loop, surrounded by regions of high
sequence diversity, suggests this structural conservation
is related to biological function. 
Many studies have shown that the alteration of one or
more amino acid residues within the stem of the V3 loop
leads to changes in viral tropism. However, it remains to
be seen whether these individual residue changes alter
the loop structure or effect a switch in β-turn conforma-
tion at the tip of the loop. Clearly, a direct consequence
of different turn types around Gly-Pro-Gly-Arg is that
the flanking regions of V3 would be in different environ-
ments based on which turn type was found at the loop tip.
The determination of the crystal structures of Fab frag-
ments in complex with V3 loop peptides, presented here,
goes some way towards understanding the conforma-
tional flexibility of this loop, although the answers to some
questions remain elusive. These unanswered questions
provide an important direction for future studies designed
to reveal the biological role of the V3 loop. Further knowl-
edge of the V3 structure will open up the possibilities for
small molecule drug design based on its three-dimensional
structure, or vaccine development through stabilization of
biologically relevant conformations.
Materials and methods
The linear Aib142 peptide was prepared by chemical synthesis using
Nα-9-fluorenylmethoxyl-carbonyl (Fmoc) protected amino acids and
Fmoc-Rink’s amide resin on an Advance Chemtech ACT350 peptide
synthesizer, following the manufacturer’s protocol. The N terminus was
acetylated and the sidechain of Cys was protected with an acetamido-
methyl (Acm) group. A mixture of trifluoroacetic acid (TFA)/phenol/ethane-
dithiol/thioanisole/water (84:6:2:4:4 v/w/v/v/v) was used to cleave the
peptide from the resin. Peptide was purified using a preparative Cos-
mosil C-18 reverse-phase column on a Gilson high-performance liquid
chromatography (HPLC) system. The peptide was eluted with a water/
acetonitrile gradient containing 0.1% trifluoroacetic acid; 0–20% ace-
tonitrile over 5 minutes followed by 20–35% acetonitrile over 20 min at
8 ml/min. The pure peptide eluted as a single peak on analytical HPLC
and its identity was confirmed by mass spectrometry. The cyclic peptides
were synthesized by solid phase synthesis using modified amino acids to
form the hydrazone link. They were purified to single peaks by HPLC and
their identities confirmed by mass spectrometry.
All crystallizations were carried out using the sitting drop, vapor diffu-
sion method at 22.5°C. Crystals of the Fab 58.2–His loop and Ser
loop complexes were obtained with a well solution containing 16%
PEG 4000, 0.2 M imidazole malate, pH 5.0. The sitting drop consisted
of 2.5 µl well solution, and 2.5 µl peptide/Fab (15 mg/ml Fab), with a
peptide:Fab molar ratio of 2.4:1. Crystals of the Fab 58.2–Aib142
complex were grown from a well solution of 16% PEG 10,000, 0.2 M
imidazole malate, pH 6.3. The drops consisted of 2.5 µl peptide/Fab
(15 mg/ml Fab), and 2.5 µl well solution with a peptide:Fab molar ratio
of 1.7:1. Space groups and unit cell dimensions for all crystal forms
were determined by precession photography. Data collection statistics
and information are tabulated for all three crystal forms in Table 1.
The Fab 58.2/Ser loop complex structure was determined first, using
coordinates of Fab 59.1 (1acy, [28]), minus its peptide, as the MR
model. Fabs 59.1 and 58.2 have approximately 83% and 65% sequence
identity respectively in their VL and VH domains; their CL and CH1
domains are identical (IgG1, κ). The structure was determined using
the X-PLOR rotation function and PC refinement [68], and a modified
Harada translation function [69] written in our laboratory by D Filman
and J Arévalo, with the intact 59.1 as a model. The intact Fab was
found to be a suitable starting model because its elbow angle (the
angle between the pseudo twofold axes of the VL – VH and CL – CH1
domains) differed from that of the unknown Fab by only 11o (the elbow
angle for 58.2 was 144° and for 59.1 was 135°). Alternating cycles of
model building with the Alberta/Caltech version of TOM/FRODO
[70,71] and refinement with the slow-cooling protocol in X-PLOR [72]
were carried out, with peptide electron density being clearly visible
after several cycles (Figure 4d). The refined coordinates for Fab 58.2–
Ser loop (minus the peptide) were used as a starting model for the iso-
morphous Fab 58.2–His loop complex (Figure 4c). The Fab coordi-
nates were refined using rigid body refinement followed by alternating
cycles of slow-cooling refinement and model building as for the Ser
loop complex. The Fab 58.2–Aib142 structure was also determined
using MR. To estimate the elbow angle for the Fab 58.2–Aib142 struc-
ture, the Crowther Fast Rotation Function, as implemented in Merlot
[73], was used to carry out cross-rotation functions with over 100 avail-
able Fab coordinate sets, which had previously been superimposed on
a reference position, with the elbow angle aligned along the z-axis. A
plot of elbow angle versus peak height for the top solution for each
model suggested an elbow angle of around 180° for the unknown Fab
58.2. The starting Fab 58.2 model coordinates (the refined 58.2–Ser
loop coordinates, without peptide) were artificially given this approxi-
mate elbow angle. The rotation function, PC refinement and translation
function from X-PLOR were used for the structure determination [68].
The actual elbow angle for the refined structure was 175°. The struc-
ture was refined and rebuilt in alternating cycles as for the two previous
complexes. Density for the peptide was very clear after only one cycle
of slow-cooling refinement and manual rebuilding of the starting Fab
model (Figure 4a,b).
Accession numbers
The coordinates and structure factors for the three Fab 58.2–peptide
complexes are deposited in the PDB with accession codes 1f58, 2f58
and 3f58, to become available at the time of publication.
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